Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bolt Biotherapeutics (BOLT) Other Accumulated Expenses (2020 - 2025)

Bolt Biotherapeutics (BOLT) has disclosed Other Accumulated Expenses for 6 consecutive years, with $288000.0 as the latest value for Q4 2025.

  • Quarterly Other Accumulated Expenses fell 24.21% to $288000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $288000.0 through Dec 2025, down 24.21% year-over-year, with the annual reading at $288000.0 for FY2025, 24.21% down from the prior year.
  • Other Accumulated Expenses hit $288000.0 in Q4 2025 for Bolt Biotherapeutics, down from $385000.0 in the prior quarter.
  • In the past five years, Other Accumulated Expenses ranged from a high of $2.0 million in Q1 2022 to a low of $288000.0 in Q4 2025.
  • Historically, Other Accumulated Expenses has averaged $832550.0 across 5 years, with a median of $820000.0 in 2021.
  • Biggest five-year swings in Other Accumulated Expenses: skyrocketed 140.54% in 2022 and later tumbled 56.07% in 2024.
  • Year by year, Other Accumulated Expenses stood at $1.2 million in 2021, then dropped by 19.62% to $963000.0 in 2022, then tumbled by 40.39% to $574000.0 in 2023, then plummeted by 33.8% to $380000.0 in 2024, then fell by 24.21% to $288000.0 in 2025.
  • Business Quant data shows Other Accumulated Expenses for BOLT at $288000.0 in Q4 2025, $385000.0 in Q3 2025, and $500000.0 in Q2 2025.